Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15133211 | 0.80 | MPO (0.37) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL23989364 | 0.79 | CACNA1G (0.34) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL24908123 | 0.78 | CACNA1G (0.32) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL22843159 | 0.76 | MAPT (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL24908241 | 0.76 | CACNA1G (0.33) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL25619087 | 0.75 | CACNA1G (0.37) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL23194293 | 0.75 | CACNA1G (0.31) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL11918294 | 0.75 | CACNA1G (0.31) | CACNA1GCACNA1HCACNA1I | |
| SCHEMBL10080926 | 0.74 | HSP90AA1 (0.33) | — | |
| SCHEMBL18997768 | 0.74 | HTR4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013823-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013823-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | CACNA1G 4186/4885CACNA1H 4216/4885CACNA1I 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.